B2BROKER
The crypto market is on an exciting growth journey, with Bitcoin hitting all-time highs and the total crypto market cap exceeding $2.37T. This coincides with the introduction of MiCA regulation, effective June 30, 2024, and followed by another wave on December 30, 2024, aiming to increase credibility and transparency, fostering wider crypto adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325324392/en/
B2Broker releases B2Trader, an industry-leading crypto spot brokerage solution. (Graphic: Business Wire)
With over 20,000 coins and tokens and a user base of over 300 million traders, compared to the FX market's 128 currency pairs and estimated 50 million traders, crypto is emerging as a more appealing trading option. Its expansion is fueled by its broad adaptation across finance, fintech, payments, and other sectors. Introducing innovative business models through technologies like L2 solutions and blockchain protocols.
To meet the booming crypto trading demand, brokerages are actively seeking solutions to enter the market. And in response, B2Broker announces the release of the B2Trader Brokerage Platform (BBP), a crypto spot broker solution designed to help businesses tap into this growing trend and start generating revenue faster than ever!
Who Can Benefit from B2Trader?
B2Trader is a powerful solution for crypto brokers (CFD and Derivatives), OTC brokers, FOREX brokers, multi-asset and multi-market brokers, market makers, liquidity providers, payment systems, and even banks to follow the market trends and enter the fastest-growing industry.
Here’s how each business model is able to utilise BBP:
FOREX Brokers
B2Trader can be an excellent addition to any FX broker. Along with the traditional trading platforms (MT4, MT5, cTrader, etc.) that mainly handle assets like FX, crypto, equity indices, and precious metals for margin trading or in the form of CFDs, you can add B2Trader to offer crypto spot trading exclusively, attract a new segment of crypto traders interested in physical delivery or ownership, and generate revenue through commissions, markups, and effective risk management.
Additionally, BBP offers a solution for regulated FX brokers to separate their digital asset trading under a different license, promoting strategic diversification and maintaining a competitive advantage in today’s market.
Crypto Brokers
Brokers focusing on crypto CFDs, using crypto as collateral, and offering a mix of FX and crypto CFDs can use B2Trader to enhance existing solutions with crypto spot trading.
Given the competitive nature of client retention and acquisition, the absence of crypto spot trading options could lead clients to seek services elsewhere. Thus, integrating B2Trader is a strategic advantage for brokerages, allowing them to adapt to market trends swiftly, offer much-demanded crypto spot trading, and meet client expectations.
Market Makers
Market makers can use B2Trader to access multiple exchanges, consolidate liquidity efficiently, achieve competitive spreads, optimise pricing, and enable smart routing execution across different venues.
Liquidity Providers
Adding cryptocurrencies to your asset offerings greatly boosts your appeal to brokers, hedge funds and professional traders. B2Trader streamlines this process, equipping you with the essential tools to expand your market reach and accelerate your earnings.
EMIs, Payment Systems, and Banks
For EMIs, PSPs, and banks, B2Trader provides a strategic edge by enabling diverse asset management, monitoring, and liquidity pool creation. It allows these entities to add crypto services to their existing operations, net all transactions, offer crypto accounts, and enable instant swaps.
BBP opens unlimited opportunities as your gateway to crypto and its booming trends. With its comprehensive API and a complete set of essential components and modules, B2Trader seamlessly integrates into any business model.
High-Speed, High-Efficiency, High-Tech
B2Trader is designed for the Enterprise scale of brokers to serve modern financial markets. Even in its most basic setup, it handles 3000 trading instruments and processes up to 3000 requests per second. It offers real-time market data, updates every 100 ms and ultra-fast order execution starting from 1 ms. This can be improved further by enhancing cloud resources and computing.
"Today, B2Broker is a leading name in the FinTech industry. We began operating in the FOREX industry in 2014 and have been developing solutions for the crypto industry since 2017. B2Broker has earned multiple awards and recognitions, and our years of experience have allowed us to understand what the market needs exactly.
That's why we created B2Trader. It's our answer to the changing trends in finance. We have poured 18 months of hard work and over $5 million into B2Trader. BBP is built by our dedicated in-house team of 40 engineers, each contributing to a solution that truly meets the demands of today's brokers. In the next 12 months, we are planning to double the team and enhance our offerings even further!"
— Arthur Azizov, CEO and Founder of B2Broker
Cutting-Edge Technology Stack
BBP focuses on reliability, scalability, and security, using the latest tools and protocols. It is hosted on AWS for its dependable infrastructure, reducing hardware risks. It utilises MongoDB and Amazon Redshift for data management and includes TradingView for market insights.
Kubernetes and Docker support scalable deployments, while CloudFlare provides DDoS protection. The FIX protocol boosts B2Trader's efficiency and reliability.
Powerful Integrations
Developed by B2Broker, B2Trader offers powerful integrations. B2Broker offers a comprehensive suite of products, including a trading platform, OMS, pre-trade and post-trade control, liquidity management system, Trading User Interface, CRM, back office, blockchain wallets for processing and collecting coins/tokens, blockchain management system for automatic payouts and settlements, mobile applications, technical documentation, REST and FIX API protocols, advanced White Label options, and much more.
Additionally, integrated with Marksman, a crypto liquidity distribution engine, B2Trader streamlines administration and ensures market updates with the latest data.
With Marksman, crypto brokers swiftly link to top exchanges by inputting API credentials after opening an account. This allows brokers to create diverse liquidity pools from various exchanges, assign specific execution and routing rules, and establish failover protocols for both the pairs and the liquidity pools.
B2Trader is available as a turnkey solution or for integration with any CRM via REST API. Contact the sales team or your account manager, try out the free demo, and launch your crypto spot broker within a week!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325324392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom